SLDB vs STRO

Solid Biosciences Inc. vs Sutro Biopharma, Inc. — Valuation Comparison 2026

SLDB

Biological Products, (No Diagnostic Substances)
Solid Biosciences Inc.
Quality
4.4
out of 10
Value Trap
18
SAFE
Price
$7.34
Last close
Models
7/13
Active
VS

STRO

Biological Products, (No Diagnostic Substances)
Sutro Biopharma, Inc.
Quality
5.6
out of 10
Value Trap
24
SAFE
Price
$29.23
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType SLDB Fair ValueSLDB Upside STRO Fair ValueSTRO Upside
Bayesian DCF Intrinsic $3.30 -55.1% $8.37 -71.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.75 -35.3% $4.73 -83.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SLDB vs STRO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SLDB vs STRO — Which Stock Is More Undervalued?

STRO scores higher with a 5.6/10 quality rating vs SLDB's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Solid Biosciences Inc. (SLDB) and Sutro Biopharma, Inc. (STRO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SLDB currently trades at $7.34 with a QOC of 4.4/10, while STRO trades at $29.23 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).